Overview of Dr. Badros
Dr. Ashraf Badros is an oncologist in Baltimore, MD and is affiliated with University of Maryland Medical Center. He received his medical degree from Ain Shams University Faculty of Medicine and has been in practice 32 years. Dr. Badros accepts several types of health insurance, listed below. He is one of 100 doctors at University of Maryland Medical Center who specialize in Oncology. He has more than 100 publications and over 500 citings.
Office
22 S. Greene St
Baltimore, MD 21201Fax+1 410-328-1975
Education & Training
- Georgetown University HospitalFellowship, Medical Oncology, 1994 - 1996
- MedStar Health/Harbor HospitalResidency, Internal Medicine, 1990 - 1993
- Ain Shams University Faculty of MedicineClass of 1985
Certifications & Licensure
- MD State Medical License 1991 - 2026
- AR State Medical License 1998 - 2002
- DC State Medical License 1994 - 1998
- NY State Medical License 1993 - 1994
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2014
Clinical Trials
- Oblimersen, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2002 Sep 01
- FR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin's Lymphoma Start of enrollment: 2004 Jan 01
- Vorinostat and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2005 Nov 01
- Join now to see all
Publications & Presentations
PubMed
- 98 citationsLonger term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study.Sagar Lonial, Hans C. Lee, Ashraf Badros, Suzanne Trudel, Ajay K. Nooka
Cancer. 2021-07-27 - 16 citationsImmune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma.Romanos Sklavenitis-Pistofidis, Michelle P Aranha, Robert A Redd, Joanna Baginska, Nicholas J Haradhvala
Cancer Cell. 2022-11-14 - 31 citationsA Phase Ib/II Study of Oprozomib in Patients with Advanced Multiple Myeloma and Waldenström Macroglobulinemia.Irene M. Ghobrial, Ravi Vij, David S. Siegel, Ashraf Badros, Jonathan L. Kaufman
Clinical Cancer Research. 2019-08-15
Abstracts/Posters
- Increased Cortical Glycolysis Following CD19 CART Therapy: A Radiographic Surrogate for an Altered Blood-Brain BarrierAshraf Z. Badros, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) after CD19-Directed Chimeric Antigen Receptor T-Cell Therapy (CAR-T) for Large B-Cell Lymphoma: Predicti...Ashraf Z. Badros, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Translational and Clinical Evidence of a Differentiated Profile for the Novel CELMoD, Iberdomide (CC-220)Ashraf Z. Badros, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Lectures
- Intravesicular Cidofovir in the Treatment of BK Virus-Associated Hemorrhagic Cystitis (BKV-HC) Following Allogeneic Hematopoietic Stem Cell Transplant (HSCT)2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Novel Approaches to Newly Diagnosed Plasma Cell Dyscrasias2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Press Mentions
- DARZALEX® (Daratumumab)-Based Maintenance Regimens Show Clinically Meaningful Deep and Durable Responses in Transplant-Eligible Patients with Newly Diagnosed Multiple MyelomaSeptember 27th, 2024
- International Myeloma Foundation Launches Baltimore-Area Campaign to Raise Disease Awareness and Improve Outcomes in the African-American CommunitySeptember 9th, 2021
- Pembrolizumab Combo Active in Relapsed/Refractory MyelomaMay 16th, 2017
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
CareFirst BCBS Maryland POS
CareFirst BlueChoice Advantage
CareFirst BlueChoice Network POS
CareFirst BluePreferred PPO
CIGNA HMO
CIGNA Open AccessCIGNA PPO
First Health PPO
Great West PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: